Actively Recruiting
Study of Influenza Vaccination to Prevent Heart Problems in Adults with Acute Coronary Syndrome
Led by Tongji Hospital · Updated on 2026-01-13
6620
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating whether influenza vaccination can reduce adverse cardiac events in Chinese patients who have acute coronary syndrome ACS. The study aims to find out if receiving the influenza vaccine decreases the risk of cardiovascular death, heart attacks, strokes, and other serious heart-related problems compared to those who receive a placebo. Participants will be randomly assigned to receive either a 0.5 ml injection of the influenza vaccine or a placebo injection after enrollment. The study includes follow-up phone calls at 1 month, 3 months, 6 months, and 1 year after hospital discharge to monitor their health and collect information about any cardiac events. During the study, researchers will track major heart-related outcomes such as cardiovascular death, myocardial infarction, stroke, unplanned hospitalizations for heart failure or arrhythmia, unplanned revascularization procedures, and stent thrombosis over 12 months. Participants will be closely monitored through scheduled follow-ups to evaluate these outcomes and overall survival during this period.
CONDITIONS
Brief Title
Influenza Vaccination After Acute Coronary Syndrome
Research Team
Y
Yang Sun
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
